tbuckley/cabot-search huggingface dataset:
A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL
Authors: Farrukh T. Awan, Shanmugapriya Thangavadivel, David Weiss, Lai Wei, Jennifer A. Woyach, Kerry A. Rogers, Jeffrey Jones, Leslie Andritsos, Natarajan Muthusamy, Barbara Andersen, John C. Byrd
Journal: Blood (2017)
Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations
Authors: Lulu Huang, Audrey Low, Sagar S. Damle, Melissa M. Keenan, Steven Kuntz, Susan F. Murray, Brett P. Monia, Shuling Guo
Journal: Genome biology (2018)

About 11% of all human genetic diseases are caused by nonsense mutations that generate premature translation termination codons (PTCs) in messenger RNAs (mRNA). PTCs not only lead to the production of truncated proteins, but also often result in decreased mRNA abundance due to nonsense-mediated mRNA decay (NMD). Although pharmacological inhibition of NMD could be an attractive therapeutic approach for the treatment of diseases caused by nonsense mutations, NMD also regulates the expression of 10–20% of the normal transcriptome. Here, we investigate whether NMD can be inhibited to stabilize mutant mRNAs, which may subsequently produce functional proteins, without having a major impact on the normal transcriptome. We develop antisense oligonucleotides (ASOs) to systematically deplete each component in the NMD pathway. We find that ASO-mediated depletion of each NMD factor elicits different magnitudes of NMD inhibition in vitro and are differentially tolerated in normal mice. Among all of the NMD factors, Upf3b depletion is well tolerated, consistent with previous reports that UPF3B is not essential for development and regulates only a subset of the endogenous NMD substrates. While minimally impacting the normal transcriptome, Upf3b-ASO treatment significantly stabilizes the PTC-containing dystrophin mRNA in mdx mice and coagulation factor IX mRNA in a hemophilia mouse model. Furthermore, when combined with reagents promoting translational read-through, Upf3b-ASO treatment leads to the production of functional factor IX protein in hemophilia mice. These data demonstrate that ASO-mediated reduction of the NMD factor Upf3b could be an effective and safe approach for the treatment of diseases caused by nonsense mutations.
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Cora N. Sternberg, Frede Donskov, Naomi B. Haas, Christian Doehn, Paul Russo, Mohamed Elmeliegy, Guillaume Baneyx, Hiya Banerjee, Paola Aimone, Robert J. Motzer
Journal: Clinical Cancer Research (2018)

Abstract Purpose: PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between pazopanib exposure (Ctrough) and efficacy and safety was evaluated. Patients and Methods: Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early Ctrough) and 250 patients at week 16 or 20 (late Ctrough). Pazopanib pharmacokinetic (PK) data were analyzed via a population model approach. Relationship between Ctrough or dose intensity and disease-free survival (DFS) was explored via Kaplan–Meier and multivariate analysis. Adverse events (AE) and AE-related treatment discontinuation proportions were summarized by Ctrough quartiles. Results: Most (&amp;gt;90%) patients with early or late Ctrough data started on 600 mg. Mean early and late Ctrough overlapped across dose levels. Patients with higher early Ctrough quartiles achieved longer DFS (adjusted HR, 0.58; 95% confidence interval, 0.42–0.82; P = 0.002). Patients achieving early or late Ctrough &amp;gt;20.5 μg/mL had significantly longer DFS: not estimable (NE) versus 29.5 months, P = 0.006, and NE versus 29.9 months, P = 0.008, respectively. Dose intensity up to week 8 did not correlate with DFS, consistent with population PK model–based simulations showing overlapping pazopanib exposure with 600 and 800 mg doses. The proportion of AE-related treatment discontinuation and grade 3/4 AEs, with the exception of hypertension, was not correlated to Ctrough. Conclusions: In the adjuvant setting, higher pazopanib Ctrough was associated with improved DFS and did not increase treatment discontinuations or grade 3/4 AEs, with the exception of hypertension. Clin Cancer Res; 24(13); 3005–13. ©2018 AACR. See related commentary by Rini, p. 2979
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial
Authors: Jean-Michel Molina, Birgit Grund, Fred Gordin, Ian Williams, Mauro Schechter, Marcello Losso, Matthew Law, Ernest Ekong, Noluthando Mwelase, Athanasios Skoutelis, Martin J Wiselka, Linos Vandekerckhove, Thomas Benfield, David Munroe, Jens D Lundgren, James D Neaton
Journal: The Lancet HIV (2018)
ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment.
Authors: Christian Diego Rolfo, Philippe Georges Aftimos, Jean-Rene Pallandre, Virginia Morello, Adeline Bouard, Manuela Cazzanti, Philippe Barthelemy, Sylvie Rottey, Ahmad Awada, Valerie Hanssens, Natalie De Jonge, Luc Van Rompaey, Samson Sau-Sing Fung, Paolo Michieli, Christophe Borg
Journal: Journal of Clinical Oncology (2016)

e14016 Background: ARGX-111 is a therapeutic antibody candidate combining three independent MoA: i. blockade of HGF-dependent and -independent MET activity, ii. enhanced ADCC and iii. increased tissue penetration through enhanced FcRn binding. A Phase-I study (NCT02055066) in patients with c-MET-amplified tumors is ongoing. A new hypothesis for depletion of MET-positive MDSCs in the tumor microenvironment is also investigated. Methods: c-MET amplification detected using FISH on tumor biopsies is a prescreening requisite for patient selection in the expansion phase. MDSCs were enumerated by FACS using blood and ascites from patients or tumor and spleen tissue from a mouse CT26 syngeneic tumor model. Results: ARGX-111 dose escalation indicated a favorable safety profile and fixed a 3 mg/kg bi-weekly dose for the safety expansion in c-MET-amplified patients. Efficacy signals were seen in the c-MET-amplified setting [J Clin Oncol 33, 2015 (suppl; abstr 2580)]. FISH screening identified 4% of c-MET-amplified biopsies (5/124; MET/CEP7 ratio: 2.5-14.1): gastric: 2/13; gall bladder: 1/8, RCC: 2/9. Treatment of the patients is ongoing and clinical results from the expansion cohort will be presented at the meeting. MET-positive MDSCs were isolated from healthy subjects, cancer patients (RFI > 2 for 4/8 patients vs. 3/8 controls) and from ascites of pancreatic cancer patients (2/2). Ex vivo depletion by ARGX-111 was observed based on its enhanced ADCC. In the CT26 syngeneic tumor model, the spleen of tumor-bearing mice displayed an increased MDSC/CD8+ cytotoxic T-cell ratio compared to control mice without tumor. MET expression was confined to monocytic MDSCs (10-25%) in the spleen while in tumor tissue, both granulocytic and monocytic MDSCs expressed MET ( > 90%). Conclusions: ARGX-111 displays a promising safety and biological activity profile in c-MET amplified patients in the ongoing Phase-I trial. Preclinical studies demonstrated depletion of MET-positive MDSCs by ARGX-111, providing an exciting new perspective for therapeutic intervention in MET cancer biology by targeting of both the tumor cells and the tumor microenvironment. Clinical trial information: NCT0205506.
Improving Diagnostic Decisions
Authors: Jayshil J. Patel, Paul Bergl
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cysteinyl Leukotriene Receptor 2 (CysLT2R) Drives Lung Immunopathology Through a High Mobility Box 1-Dependent Mechanism
Authors: Tao Liu, Nora A. Barrett, Yoshihide Kanaoka, Tanya M. Laidlaw, Eri Yoshimoto, Denise Garofalo, Chunli Feng, Joshua A. Boyce
Journal: Journal of Allergy and Clinical Immunology (2018)
Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33
Authors: Chloé Michaudel, Claire Mackowiak, Isabelle Maillet, Louis Fauconnier, Cezmi A. Akdis, Milena Sokolowska, Anita Dreher, Hern-Tze Tina Tan, Valérie F. Quesniaux, Bernhard Ryffel, Dieudonnée Togbe
Journal: Journal of Allergy and Clinical Immunology (2018)

IL-33 plays a critical role in regulation of tissue homeostasis, injury, and repair. Whether IL-33 regulates neutrophil recruitment and functions independently of airways hyperresponsiveness (AHR) in the setting of ozone-induced lung injury and inflammation is unclear.We sought to examine the role of the IL-33/ST2 axis in lung inflammation on acute ozone exposure in mice.ST2- and Il33-deficient, IL-33 citrine reporter, and C57BL/6 (wild-type) mice underwent a single ozone exposure (1 ppm for 1 hour) in all studies. Cell recruitment in lung tissue and the bronchoalveolar space, inflammatory parameters, epithelial barrier damage, and airway hyperresponsiveness (AHR) were determined.We report that a single ozone exposure causes rapid disruption of the epithelial barrier within 1 hour, followed by a second phase of respiratory barrier injury with increased neutrophil recruitment, reactive oxygen species production, AHR, and IL-33 expression in epithelial and myeloid cells in wild-type mice. In the absence of IL-33 or IL-33 receptor/ST2, epithelial cell injury with protein leak and myeloid cell recruitment and inflammation are further increased, whereas the tight junction proteins E-cadherin and zonula occludens 1 and reactive oxygen species expression in neutrophils and AHR are diminished. ST2 neutralization recapitulated the enhanced ozone-induced neutrophilic inflammation. However, myeloid cell depletion using GR-1 antibody reduced ozone-induced lung inflammation, epithelial cell injury, and protein leak, whereas administration of recombinant mouse IL-33 reduced neutrophil recruitment in Il33-deficient mice.Data demonstrate that ozone causes an immediate barrier injury that precedes myeloid cell-mediated inflammatory injury under the control of the IL-33/ST2 axis. Thus IL-33/ST2 signaling is critical for maintenance of intact epithelial barrier and inflammation.
Inhalation of peptide-loaded nanoparticles improves heart failure
Authors: Michele Miragoli, Paola Ceriotti, Michele Iafisco, Marco Vacchiano, Nicolò Salvarani, Alessio Alogna, Pierluigi Carullo, Gloria Belén Ramirez-Rodríguez, Tatiana Patrício, Lorenzo Degli Esposti, Francesca Rossi, Francesca Ravanetti, Silvana Pinelli, Rossella Alinovi, Marco Erreni, Stefano Rossi, Gianluigi Condorelli, Heiner Post, Anna Tampieri, Daniele Catalucci
Journal: Science Translational Medicine (2018)

Inhalation delivers drug-loaded nanoparticles to the heart, improving cardiac function in murine and porcine models.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Authors: Gerrit J. Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K. Hills, Christopher S. Hourigan, Jeffrey L. Jorgensen, Wolfgang Kern, Francis Lacombe, Luca Maurillo, Claude Preudhomme, Bert A. van der Reijden, Christian Thiede, Adriano Venditti, Paresh Vyas, Brent L. Wood, Roland B. Walter, Konstanze Döhner, Gail J. Roboz, Gert J. Ossenkoppele
Journal: Blood (2018)
Bone minderal density screening in a pediatric population with eosinophilic esophagitis
Authors: Ellen Martin, Megan Patterson, Sarah Beckwith, Mallikarjuna Rettiganti, Chunqiao Luo, Peggy L. Chandler, Christina Tootle, Rebecca Levy, Amy M. Scurlock, Stacie M. Jones, Robbie D. Pesek
Journal: Journal of Allergy and Clinical Immunology (2018)
Deoxycorticosterone acetate-salt hypertension activates placental growth factor in the spleen to couple sympathetic drive and immune system activation
Authors: Marialuisa Perrotta, Andrea Lori, Lorenzo Carnevale, Stefania Fardella, Giuseppe Cifelli, Roberta Iacobucci, Francesco Mastroiacovo, Daniele Iodice, Fabio Pallante, Marianna Storto, Giuseppe Lembo, Daniela Carnevale
Journal: Cardiovascular Research (2018)

Chronic increase of mineralocorticoids obtained by administration of deoxycorticosterone acetate (DOCA) results in salt-dependent hypertension in animals.Despite the lack of a generalized sympathoexcitation, DOCA-salt hypertension has been also associated to overdrive of peripheral nervous system in organs typically targeted by blood pressure (BP), as kidneys and vasculature.Aim of this study was to explore whether DOCA-salt recruits immune system by overactivating sympathetic nervous system in lymphoid organs and whether this is relevant for hypertension......
Towards an international language for incontinence-associated dermatitis (IAD): design and evaluation of psychometric properties of the Ghent Global IAD Categorization Tool (GLOBIAD) in 30 countries
Authors: D. Beeckman, K. Van den Bussche, P. Alves, M.C. Arnold Long, H. Beele, G. Ciprandi, F. Coyer, T. de Groot, D. De Meyer, E. Deschepper, A.M. Dunk, A. Fourie, P. García-Molina, M. Gray, A. Iblasi, R. Jelnes, E. Johansen, A. Karadağ, K. Leblanc, Z. Kis Dadara, S. Meaume, A. Pokorna, M. Romanelli, S. Ruppert, L. Schoonhoven, S. Smet, C. Smith, A. Steininger, M. Stockmayr, N. Van Damme, D. Voegeli, A. Van Hecke, S. Verhaeghe, K. Woo, J. Kottner
Journal: British Journal of Dermatology (2018)

Incontinence‐associated dermatitis (IAD) is a specific type of irritant contact dermatitis with different severity levels. An internationally accepted instrument to assess the severity of IAD in adults, with established diagnostic accuracy, agreement and reliability, is needed to support clinical practice and research. To design the Ghent Global IAD Categorization Tool (GLOBIAD) and evaluate its psychometric properties. The design was based on expert consultation using a three‐round Delphi procedure with 34 experts from 13 countries. The instrument was tested using IAD photographs, which reflected different severity levels, in a sample of 823 healthcare professionals from 30 countries. Measures for diagnostic accuracy (sensitivity and specificity), agreement, interrater reliability (multirater Fleiss kappa) and intrarater reliability (Cohen's kappa) were assessed. The GLOBIAD consists of two categories based on the presence of persistent redness (category 1) and skin loss (category 2), both of which are subdivided based on the presence of clinical signs of infection. The agreement for differentiating between category 1 and category 2 was 0·86 [95% confidence interval (CI) 0·86–0·87], with a sensitivity of 90% and a specificity of 84%. The overall agreement was 0·55 (95% CI 0·55–0·56). The Fleiss kappa for differentiating between category 1 and category 2 was 0·65 (95% CI 0·65–0·65). The overall Fleiss kappa was 0·41 (95% CI 0·41–0·41). The Cohen's kappa for differentiating between category 1 and category 2 was 0·76 (95% CI 0·75–0·77). The overall Cohen's kappa was 0·61 (95% CI 0·59–0·62). The development of the GLOBIAD is a major step towards a better systematic assessment of IAD in clinical practice and research worldwide. However, further validation is needed.
Efficacy and Toxic Effects of Cancer Immunotherapy Combinations—A Double-edged Sword
Authors: Chad Tang, Wen Jiang, Timothy A. Yap
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 14579: Peak Myocardial Blood Flow versus Noninvasive Coronary Flow Reserve for Prediction of Future Events
Authors: Mouaz H Al-Mallah, Ahmed Aljizeeri, Dalia Ahmed, Mousa Alfaris, Abdulbaset Suleiman, Ihab Suliman
Journal: Circulation (2015)

Background: Impaired coronary flow reserve (CFR) is an early manifestation of coronary artery disease (CAD), even in vessels free of angiographic stenosis. The aim of this analysis is to determine the differential role peak myocardial blood flow (MBF) or noninvasive CFR in predicting future events. Methods: We included 3,003 consecutive patients with known or suspected CAD (mean age 61±11years, 42% females) who underwent rubidium-82 rest/stress positron emission tomography (PET) for clinical indications. Rest and peak MBF were calculated with factor analysis and a 2-compartment kinetic model and were used to calculate CFR. Patients were followed up for a median duration of 1.4 years (interquartile range, 0.5-1.8 years) for the incidence of cardiac death or myocardial infarction. (CDMI). Multiple Cox regression models were used to determine the prognostic value of peak MBF and CFR and the incremental value of peak MBF over CFR. Results: The included cohort has prevalence of CAD risk factors: Diabetes (60%), hypertension (87%) and dyslipidemia (85%). A total of 40% patients had evidence of perfusion defects (Sum stress score&gt;3). After a median follow up duration of 1.4 years, 140 patients (4.7%) experienced CD/MI. In multivariate Cox regression adjusted for Duke clinical risk score, resting ejection fraction and SSS, both CFR (Hazard Ratio 0.70, 95% CI 0.54 -0.89, p=0.005) and peak MBF (Hazard Ratio 0.71, 95% CI 0.57 -0.89, p=0.003) were independent predictors of CDMI. (Adding peak MBF added incremental prognostic value over CFR. (Area under the curve increased from 0.776 to 0.793, p=0.021). Conclusion: Noninvasively measured MBF and CFR are independent predictors of CDMI in patients with known or suspected CAD. Peak MBF adds incremental prognostic value over noninvasive CFR.
Changes in Health Care Use Associated With the Introduction of Hospital Global Budgets in Maryland
Authors: Eric T. Roberts, J. Michael McWilliams, Laura A. Hatfield, Sule Gerovich, Michael E. Chernew, Lauren G. Gilstrap, Ateev Mehrotra
Journal: JAMA Internal Medicine (2018)

In 2014, the State of Maryland placed the majority of its hospitals under all-payer global budgets for inpatient, hospital outpatient, and emergency department care. Goals of the program included reducing unnecessary hospital utilization and encouraging greater use of primary care.
Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience
Authors: Ajai Chari, Dorothy Romanus, Katarina Luptakova, Aditya Raju, Eileen Farrelly, Marlo Blazer, Tomas Skacel, Parameswaran Hari
Journal: Blood (2017)
Comprehensive Genomic Profiling (CGP) Identifies Novel BCL6 Rearrangements in Diverse Subtypes of Non-Hodgkin Lymphoma (NHL) As Well As Known Rearrangements Not Detected Using Standard of Care (SOC) Assays
Authors: Jo-Anne Vergilio, Lei Zhong, Mark Rosenzweig, Yakov Chudnovsky, Jie He, Michelle Nahas, Siraj M Ali, Sugganth Daniel, Shakti Ramkissoon, James Suh, Julia A Elvin, Tariq I Mughal, Philip J Stephens, Vincent A Miller, Rachel Erlich, Jeffrey S Ross, Eric A Severson, Samantha Morley
Journal: Blood (2017)
Progression of Myopic Maculopathy during 18-Year Follow-up
Authors: Yuxin Fang, Tae Yokoi, Natsuko Nagaoka, Kosei Shinohara, Yuka Onishi, Tomoka Ishida, Takeshi Yoshida, Xian Xu, Jost B. Jonas, Kyoko Ohno-Matsui
Journal: Ophthalmology (2018)
Crizotinib versus Chemotherapy in Advanced <i>ALK</i>-Positive Lung Cancer
Journal: New England Journal of Medicine (2015)

BACKGROUND: 
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK ) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown. 

METHODS: 
We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen. Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a separate study. The primary end point was progression-free survival. 

RESULTS: 
The median progression-free survival was 7.7 months in the crizotinib group and 3.0 months in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001). The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001). An interim analysis of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P=0.54). Common adverse events associated with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea. Patients reported greater reductions in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.

CONCLUSIONS: 
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.) Copyright © 2013 Massachusetts Medical Society.